Thank you, Mr. Chair.
Thank you to the witnesses for being here today. I really appreciate the timely provision of your written briefing. We had access to that over the weekend, and it helped us greatly. So thank you for that.
I'm going to be asking Mr. Ethier from Health Canada a question in a moment, some specifics of how we manage substances once they're on the schedule 1 list, if you could prepare a couple of comments on that.
Mr. Winfield said rightly that the science is clear if the substance is toxic or not, and he said that once it's on schedule 1, where do you go from there? I think that's a good question, and that's where I'd like to go. Mr. Hamilton said if a substance isn't going to be regulated it shouldn't be on the schedule 1 list. So what I'd like is a healthy discussion on approaches to management of substances. Once they're on the schedule 1 list, should they be voluntarily dealt with or should they be regulated? I appreciate the comments from each of you.
I'd like to start with Mr. Ethier from Health Canada and get his perspective, maybe some specific examples of how substances are managed.